Mount Sinai Study Unveils Lung-Sparing Surgery's Promise for Mesothelioma Patients
NEW YORK, February 12, 2026 - A groundbreaking study from the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center has shed new light on the potential of lung-sparing surgery for pleural mesothelioma, a rare and aggressive cancer often linked to asbestos exposure. The research, published in The Annals of Thoracic Surgery, challenges the widely debated Mesothelioma and Radical Surgery 2 (MARS2) trial, offering a compelling case for the safety and effectiveness of pleurectomy/decortication in carefully selected patients.
The Lung-Sparing Approach: A New Perspective
The study reveals that lung-sparing surgery, specifically pleurectomy/decortication, can be performed with remarkable safety and low mortality rates in patients with pleural mesothelioma. This modern, data-driven approach contradicts the MARS2 trial's findings, which raised concerns about surgery's role in mesothelioma treatment. The Mount Sinai team's research found zero in-hospital mortality and a 90-day mortality rate of just 4.2%, significantly lower than the MARS2 trial's rates.
A Journey of Surgical Innovation
This study builds upon nearly two decades of influential research by Dr. Raja M. Flores, a pioneer in the field. His landmark 2008 study, analyzing outcomes from 663 patients, compared pleurectomy/decortication with extrapleural pneumonectomy, a more radical surgery. The results validated lung-sparing surgery as a legitimate and often preferable option for appropriately selected patients, marking a paradigm shift in mesothelioma treatment.
Modern Techniques, Improved Outcomes
The latest study extends this shift, demonstrating that with modern imaging, rigorous preoperative evaluation, and careful surgical planning, pleurectomy/decortication can be performed with very low early mortality. This evolution in mesothelioma surgery has shifted the focus from debating the best long-term outcomes to establishing contemporary benchmarks for safety and patient selection.
Challenging the Status Quo
The MARS2 trial's higher early mortality rates and questions about surgery's value for pleural mesothelioma have sparked debate. The Mount Sinai researchers suggest that differences in patient selection, imaging use, tumor subtype, and surgical approach may have contributed to these outcomes. In their cohort, nearly 80% of patients had the epithelioid subtype of mesothelioma, known to respond better to surgical treatment, and all patients underwent rigorous preoperative testing.
A Ray of Hope for Mesothelioma Patients
Mesothelioma remains a devastating disease with limited treatment options, making it crucial to identify safe and effective approaches. Dr. Flores emphasizes that surgery should remain part of the conversation for mesothelioma treatment, especially in experienced, high-volume centers, where pleurectomy/decortication can be an effective component of multidisciplinary care.
The Mount Sinai Legacy
Mount Sinai's legacy in mesothelioma research and treatment is profound. The late Dr. Irving J. Selikoff, a physician-scientist, played a pivotal role in establishing the link between asbestos exposure and mesothelioma, leading to modern asbestos regulations. Today, Mount Sinai continues this legacy with one of the largest mesothelioma programs in the world, caring for patients exposed during the September 11, 2001, attacks.
Looking Ahead: Combining Surgery and Immunotherapy
The research team is expanding this work by studying the outcomes of combining surgery and immunotherapy for pleural mesothelioma. The study was conducted without external funding, and the full research is available for public access.
A Call for Discussion
This study invites further discussion and debate, encouraging readers to share their thoughts and opinions in the comments section. The controversy surrounding mesothelioma treatment and the role of surgery is an important topic, and the research team welcomes diverse perspectives. Are you in agreement or disagreement with the findings? Share your thoughts and join the conversation!
